CCR7 and classic Hodgkin lymphoma: We previously reported that decitabine‐plus‐camrelizumab therapy resulted in incremental increase of circulating CCR7+CD45RA− central memory T (Tcm) cells in patient with relapsed/refractory cHL, especially those who acquired CR.13, 14